12.3Ovulation induction in in vitro fertilisation: natural cycles and stimulated cycles

StudyPopulationInterventionOutcomesResultsCommentsStudy typeEL
MacDougall et al. 199483730 women for IVFClomifene citrate-stimulated cycle (n = 16) versus no treatment (n = 14)Clinical pregnancy rate/ET

Multiple pregnancy rate

No. of embryos transferred

Cycle cancellation (due to premature LH surge and poor follicular growth)
Non-significant difference:

Clinical pregnancy rate/ET:
Clomifene: 2/11 (18%)
Natural: 0/4 (0%)

Multiple pregnancy rate: 2 singletons in clomifene group

No. of embryos transferred:
Clomifene: 11/16 (69%)
Natural: 4/14 (28.6%)
RR 2.41 (CI 0.99 to 5.87)

Significant difference:
Cycle cancellation:
Clomifene: 0
Natural: 10
Randomisation using computer-selected numbersRCTIb
Ingerslev et al. 2001838132 couples for IVFClomifene citrate cycle (n = 68; 111 cycles) versus natural cycle (n = 64, 114 cycles)Implantation rate/ET

Clinical pregnancy rate/cycle

Clinical pregnancy rate/transfer

Adverse effects (nausea, hot flushes, mammary tenderness, visual disturbances)
Non-significant difference:

Implantation rate/ET:
Clomifene: 22/85 (26%)
Natural: 4/29 (14%)
RR 1.88 (CI 0.71 to 4.99)

Significant difference:
Clinical pregnancy rate/cycle:
Clomifene: 20/111 (18%)
Natural: 4/114 (3.5%)
RR 5.14 (CI 1.81 to 14.55)

Clinical pregnancy rate/transfer:
Clomifene: 20/59 (34%)
Natural: 4/29 (14%)
RR 2.46 (CI 0.92 to 6.53)

Adverse effects:
CC: 51/111 (46%)
Natural: 2/114 (1.7%)
RR 26.19 (CI 6.53 to 104.98)
Block randomisation by sealed envelopeRCTIb
Levy et al. 199183929 women for IVF-EThMG cycle (n = 13, 26 cycles) versus natural cycle (n = 16, 22 cycles)Clinical pregnancy rate/cycle

Cancellation rate

No. of embryos transferred

Multiple pregnancy rate

Adverse effects
Significant difference:

Clinical pregnancy rate/cycle:
hMG cycle: 6/26 (23%)
Natural cycle: 0/22 (0%)

Cancellation rate ‘higher’ in natural cycle (no data)

No. of embryos transferred:
hMG cycle: 23/26 (88%)
Natural cycle: 11/22(50%)
RR 1.14 (CI 1.77 to 2.75)
Multiple pregnancy rate: no data

Adverse effects: no data
Method of randomisation unclear

Cycles monitored with ultrasound and E2

Ultrasound guided transvaginal follicles aspiration

Crossover study
RCTIb

From: Evidence tables

Cover of Fertility
Fertility: Assessment and Treatment for People with Fertility Problems.
NICE Clinical Guidelines, No. 11.
National Collaborating Centre for Women's and Children's Health (UK).
London (UK): RCOG Press; 2004 Feb.
Copyright © 2004, National Collaborating Centre for Women’s and Children’s Health.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.